In people with deep vein thrombosis (DVT), the rates of major bleeding and recurrent blood clots for Xarelto (rivaroxaban) in routine clinical practice were generally consistent with those observed in Phase 3 research, according to Janssen Pharmaceuticals and Bayer HealthCare.

The companies’ real-world study XALIA — which was presented at the 2015 American Society of Hematology Annual Meeting and simultaneously published in Lancet Hematology — also revealed that patients taking Xarelto had shorter length of hospital stays than those given standard anticoagulation.

Key XALIA findings included:

  • Major bleeding occurred in 0.8% of patients receiving Xarelto and 2.1% of those receiving standard anticoagulation.
    • There were no fatal bleeding events in the Xarelto group; two fatal bleeding events occurred in the standard anticoagulation group.
  • Recurrent blood clots occurred in 1.4% of patients receiving Xarelto and 2.3% of those receiving standard anticoagulation.
  • All-cause mortality occurred in 0.4% of patients taking Xarelto and 3.4% of those taking standard anticoagulation.